Regulation - LGIC
Proposed amendments to Regulation 552 (General) under the Health Insurance Act, the Schedule of Benefits for Laboratory Services ("SOB-LS") under Regulation 552 and Regulation 682 (Laboratories) under the Laboratory and Specimen Collection Centre Licensing Act.
Regulation Number(s):
682, 552
Instrument Type:
Regulation - LGIC
Bill or Act:
Laboratory and Specimen Collection Centre Licensing Act (LSCCLA), Health Insurance Act (HIA)
Summary of Decision:
Made: June 11, 2020
Filed: June 12, 2020
Published on e-Laws: June 12, 2020
Printed in The Ontario Gazette: June 27, 2020
Filed: June 12, 2020
Published on e-Laws: June 12, 2020
Printed in The Ontario Gazette: June 27, 2020
Analysis of Regulatory Impact:
The ministry anticipates no new administrative costs or burdens if the proposed amendments to support Mucopolysaccharidosis I (MPS I) and Spinal Muscular Atrophy screening through the NSO program are approved by government.
Further Information:
Regulation 682
Proposal Number:
20-HLTC019
Posting Date:
May 15, 2020
Summary of Proposal:
The ministry is enhancing newborn screening by proposing to include Mucopolysaccharidosis I (MPS I) and Spinal Muscular Atrophy (SMA) as new screening tests under the NSO program. The NSO program is administered by the Children's Hospital of Eastern Ontario.
The addition of the new screening tests would allow for earlier detection, enabling timely intervention and treatment for improved health outcomes.
To enable implementation of the Mucopolysaccharidosis I (MPS I) and Spinal Muscular Atrophy screening tests, the ministry is proposing amendments to Regulation 682 under the LSCCLA, Regulation 552 under the HIA and the SOB-LS under Regulation 552. The proposed amendments are as follows:
The proposed amendments to Regulation 682 include:
- Amending paragraph 6 of section 4(1) to include Mucopolysaccharidosis I (MPS I) and Spinal Muscular Atrophy as newborn screening tests.
- Amending "Appendix B Tests that a Midwife may request" by adding the words Mucopolysaccharidosis I (MPS I) and Spinal Muscular Atrophy to item # 8.
The proposed amendment to Regulation 552 (General) includes:
- Amending the defined term "schedule of laboratory benefits" in section 1(1) to reflect an effective date of July 1, 2020.
The proposed amendment to the SOB-LS under Regulation 552 includes:
- Adding Mucopolysaccharidosis I (MPS I) and Spinal Muscular Atrophy to L022 as a newborn screening test; and
- Updating the effective date on the SOB-LS document.
The addition of the new screening tests would allow for earlier detection, enabling timely intervention and treatment for improved health outcomes.
To enable implementation of the Mucopolysaccharidosis I (MPS I) and Spinal Muscular Atrophy screening tests, the ministry is proposing amendments to Regulation 682 under the LSCCLA, Regulation 552 under the HIA and the SOB-LS under Regulation 552. The proposed amendments are as follows:
The proposed amendments to Regulation 682 include:
- Amending paragraph 6 of section 4(1) to include Mucopolysaccharidosis I (MPS I) and Spinal Muscular Atrophy as newborn screening tests.
- Amending "Appendix B Tests that a Midwife may request" by adding the words Mucopolysaccharidosis I (MPS I) and Spinal Muscular Atrophy to item # 8.
The proposed amendment to Regulation 552 (General) includes:
- Amending the defined term "schedule of laboratory benefits" in section 1(1) to reflect an effective date of July 1, 2020.
The proposed amendment to the SOB-LS under Regulation 552 includes:
- Adding Mucopolysaccharidosis I (MPS I) and Spinal Muscular Atrophy to L022 as a newborn screening test; and
- Updating the effective date on the SOB-LS document.
Contact Address:
1075 Bay Street, 9th Floor
Toronto, ON M7A 0A5
Toronto, ON M7A 0A5
Effective Date:
July 1, 2020
Decision:
Approved